Healthcare Services

Rising autoimmune diseases are influencing the encephalomyelitis market

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Encephalomyelitis Market Expected To Change From 2026 To 2030?

The encephalomyelitis market has demonstrated strong growth over recent years. It is anticipated to expand from $22.58 billion in 2025 to $24.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. This historical growth can be linked to the prevalence of neurological diseases, increased recognition of autoimmune disorders, greater access to diagnostic imaging, the expansion of specialist neurology, and the development of hospital neurology departments.

The encephalomyelitis market is projected to experience substantial expansion over the coming years. By 2030, this market is anticipated to reach $30.84 billion, demonstrating a compound annual growth rate (CAGR) of 6.4%. This projected growth during the forecast period can be attributed to factors such as advancements in immunotherapies, initiatives for early diagnosis programs, the increasing demand for neurological rehabilitation, expanded research into rare neurological diseases, and improvements in healthcare infrastructure. Key trends expected during the forecast period involve a heightened awareness of neuroinflammatory disorders, a rise in the diagnosis of autoimmune neurological conditions, a growing need for long-term neurological care, the proliferation of immunomodulatory treatment strategies, and an emphasis on early neurological intervention.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/encephalomyelitis-global-market-report

What Primary Drivers Are Shaping The Encephalomyelitis Market?

The increasing occurrence of autoimmune conditions is anticipated to drive expansion in the encephalomyelitis market in the future. These diseases are characterized by the immune system erroneously attacking the body’s own healthy cells and tissues. The surge in autoimmune diseases stems from various factors, including genetic tendencies, environmental provocations, infections, and shifts in lifestyle, encompassing dietary habits and chemical exposure. Treatment for encephalomyelitis aids individuals with autoimmune diseases by diminishing inflammation, addressing immune system irregularities, easing neurological signs, and hindering disease advancement, consequently enhancing their general quality of life and functional state. For example, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, indicates that by 2025, approximately 212,136 males and 362,137 females are forecast to suffer from rheumatoid arthritis (RA). These figures are predicted to increase further by 2040, reaching around 280,040 males and 479,828 females. Consequently, the increasing incidence of autoimmune diseases is fueling the expansion of the encephalomyelitis market.

Which Segment Categories Are Included In The Encephalomyelitis Market Segment Analysis?

The encephalomyelitis market covered in this report is segmented –

1) By Type: Equine Encephalomyelitis, Associated Encephalomyelitis, Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG), Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis, Other Types

2) By Treatment: Surgery, Plasmapheresis, Drug Treatment, Other Treatments

3) By End-users: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Equine Encephalomyelitis: Eastern Equine Encephalomyelitis, Western Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis

2) By Associated Encephalomyelitis: Post-Infectious Encephalomyelitis, Paraneoplastic Encephalomyelitis, Vaccine-Associated Encephalomyelitis

3) By Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG): MOG Antibody-Positive Encephalomyelitis, MOG Antibody-Associated Neuromyelitis Optica Spectrum Disorder

4) By Encephalomyelitis Disseminata: Multiple Sclerosis-Related Encephalomyelitis, Relapsing-Remitting Encephalomyelitis Disseminata, Progressive Encephalomyelitis Disseminata

5) By Acute Disseminated Encephalomyelitis: Post-Viral Acute Disseminated Encephalomyelitis, Post-Vaccination Acute Disseminated Encephalomyelitis

6) By AIDS-Related Encephalomyelitis: HIV-Associated Encephalomyelitis, Opportunistic Infection-Related Encephalomyelitis, Other AIDS-Related Encephalomyelitis

7) By Other Types: Idiopathic Encephalomyelitis, Autoimmune Encephalomyelitis, Rare Genetic Encephalomyelitis Variants

What Trends Are Affecting The Growth Of The Encephalomyelitis Market?

Leading companies in the encephalomyelitis market are prioritizing the creation of advanced monoclonal antibodies, aiming to boost treatment effectiveness and formulate targeted therapies for managing encephalomyelitis. A monoclonal antibody is an artificially engineered protein that binds to specific antigens to support the immune response against various diseases. As an example, in March 2023, Chugai Pharmaceutical Co. Ltd, a Japan-based pharmaceutical company, declared that its humanized anti-IL-6 receptor monoclonal antibody, Enspryng, received forerunner designation from the Ministry of Health, Labor and Welfare (MHLW). This designation is for its intended application in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). Such a designation acknowledges Enspryng’s potential as an innovative treatment, thereby speeding up its development and regulatory review to address the unmet medical needs of patients suffering from these neurological conditions.

Who Are The Active Companies Shaping The Encephalomyelitis Market?

Major companies operating in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.

Get The Full Encephalomyelitis Market Report:

https://www.thebusinessresearchcompany.com/report/encephalomyelitis-global-market-report

Which Geographic Region Dominates The Encephalomyelitis Market?

North America was the largest region in the encephalomyelitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the encephalomyelitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Encephalomyelitis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/encephalomyelitis-global-market-report

Browse Through More Reports Similar to the Global Encephalomyelitis Market 2026, By The Business Research Company

Encephalitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/encephalitis-treatment-global-market-report

Hepatic Encephalopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Esophageal Dysphagia Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-dysphagia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795